Novel associations are still under evaluation, such as CPX 351 plus venetoclax in ND AML without FLT3 or IDH mutations (NCT04075747) or a low-intensity dose of CPX 351 plus venetoclax in ND AML patients who are ineligible for IC. This evidence concerns the gene FLT3 and acute myeloid leukemia.